Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Journal reference: Cummings JL, Atri A, Sano M, et al
Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection licensed in Great Britain for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea, as an adjunct to diet and physical activity
This means that the patent will expire on March 20, 2026.
Cardiometabolic Improvements May reduce cholesterol, triglycerides, blood pressure, and inflammation
The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis
J.HolmesS
US$ 22.42
US$ 26.58
US$ 28.53
US$ 20.59
